Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis
NCT00832364 · Stiefel, a GSK Company · PHASE4 · withdrawn · last registry update 2015-04-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business decision. No patients were enrolled” | – | Registry record, Stiefel, a GSK Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RXRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-02-17Results posted on the registry: Vanderbilt University, Rosiglitazone and Bexarotene (NCT00178841)
- 2016-02-12Results posted on the registry: The Cleveland Clinic, Bexarotene + Placebo (NCT01782742)
- 2015-04-21Also stopped (terminated): Merck Sharp & Dohme LLC, vorinostat + Comparator: bexarotene (NCT00127101)
- 2015-02-16Results posted on the registry: University of Medicine and Dentistry of New Jersey, acitretin (NCT00156247)
- 2014-12-15Results posted on the registry: University of Washington, vorinostat (NCT00958074)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision